European medicines group appoints Bayer’s Alex Moscho as new chair
pharmafile | July 7, 2015 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Alexander Moscho, EMG, European Medicines Group
Leading UK industry group the European Medicines Group (EMG) has elected Dr Alexander Moscho, the managing director of Bayer UK & Ireland, as its new chair, taking over from Merck-Serono’s David Garmon-Jones.
Moscho will be supported in his new role by Zinta Krumins, managing director of Boehringer Ingelheim, who has been re-elected as vice-chair for the group and Mike Sumpter, managing director of Servier, who remains as Treasurer.
EMG represents the UK operations of 18 research-driven pharmaceutical companies that are headquartered in continental Europe, which includes some of the biggest pharma firms in the UK industry.
Speaking following his appointment Moscho said: “It is a privilege to be elected as chair. EMG will work with our stakeholders to ensure we play our part in creating a sustainable future for patients in the UK and for our industry’.
He added: “With the growing focus on the European Union and the future shape of the UK’s relationship with Europe generally, EMG’s views on the UK pharmaceutical industry’s place within this, becomes even more relevant.”
Vice-chair Zinta Krumins comments: “A priority for the European Medicines Group is ensuring policy makers recognise the link between the commercial environment – the local use of the medicines we research, develop and manufacture – and inward investment by our European-based HQs in its various forms into the UK. Local levels of usage of medicines and the attitude to industry cannot be separated from other policy issues and it’s an EMG priority to ensure this is better understood and is an integral part of the ongoing Accelerated Access Review.”
Related Content
Working Life: Bayer UK & Ireland’s chief executive Alexander Moscho
How did you find your way into your current role?I think it started when I …
The European Medicines Group: focused on UK market access
Maintaining a dialogue with government, NHS organisations and other stakeholder groups is essential for pharma …
Representing medium-sized pharma
UCB’s Matthew Speers is the new chairman of the European Medicines Group, which represents European-owned …
